N/A N=86 Sedation and Pain (The Effect of IV Sedation on Pain Perception)
Pain
Primary: Pain Rating Change — -0.253; 0.762; -0.346 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=90 A Study of Avastin (Bevacizumab) in Combination With Taxane-based Chemotherapy as First Line Treatment in Patients With HER-2 Negative Breast Cancer
Breast Cancer
Primary: Progression-free Survival — 11.51 Months
Phase 3 N=45 Quillivant Oral Suspension (Quillivant XR) in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores at Hour 4 Post-Dose — 7.1; 19.3 units on a scale — p=<0.0001
Phase 2 N=403 Safety and Efficacy of Once-Daily KRP-104 in Type 2 Diabetics With Inadequate Glycemic Control on Metformin Alone
Type 2 Diabetes
Primary: Change in HbA1c From Baseline (Week 0) to Week 24 — -0.09; -0.41; -0.70; -0.71 % HbA1c
Phase 2 N=153 A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
Breast Cancer
Primary: Percentage of Participants With a Cardiac Event Within 12 Weeks After the Start of Trastuzumab Emtansine Treatment — 0 Percentage of participants
Phase 3 N=22 Trial to See if Topical Pennsaid for Knee Pain Affects Coagulation Values in Patients Who Are Also Taking Anticoagulants
Osteoarthritis of the Knee · Coagulopathy
Primary: Change From Baseline to Week 4 in Laboratory Results of Prothrombin Time (PT) — 6.97; 0.96; -0.04 seconds
Phase 2 N=22 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
Insular Thyroid Cancer · Recurrent Thyroid Cancer · Stage II Follicular Thyroid Cancer
Primary: Objective Tumor Response Rate Assessed by RECIST — 0 participants
N/A N=32 Utilizing Exhaled Breathe Condensate Collection to Study Ion Regulation in Cystic Fibrosis
Cystic Fibrosis · Healthy
Primary: Exhaled Sodium (mmol/L) — 2.58; 2.24; 1.97; 2.11 mmol/L
Phase 2 N=40 A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
Sedation · Anxiety · Pain
Primary: Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4) — -5.44; 0.79 units on a scale — p=<0.001
N/A N=117 Safety and Efficacy of Endotracheal Intubation Using Glidescope Video-Laryngoscope
Respiratory Failure
Primary: First Pass Success Rate — 24; 42 percentage of first pass success
Phase 3 N=313 A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma
Lymphoma
Primary: Treatment Failure - Percentage of Participants With an Event — 68; 67 percentage of participants
N/A N=9 Assessment Of Vascular Health After Niacin Therapy (AVANT)
Coronary Artery Disease · Carotid Artery Disease · Peripheral Artery Disease
Primary: Change From Baseline in Arterial Fluorodeoxyglucose (FDG) Uptake Assessed by FDG-PET/CT — -0.02; -0.05 Target to Background Ratio (TBR)
Phase 3 N=20 An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Therapeutic Treatment of Inhalation Anthrax
Primary: Number of Participants Who Developed a Positive Anti-raxibacumab Antibody Response — 0 Participants
Phase 1 N=61 Cognitive Behavioral Therapy for the Treatment of Seasonal Affective Disorder (SAD)
Seasonal Affective Disorder · Depression
Primary: Scores on the Structured Interview Guide for the Hamilton Depression Rating Scale-Seasonal Affective Disorder Version — 13.6; 13.3; 8.3; 22.6 units on a scale
Phase 4 N=17 Pharmacokinetics of Single-Dose Oral Ranolazine in Hemodialysis Patients
End-stage Renal Disease · Cardiovascular Disease
Primary: Pharmacokinetic Parameters of Ranolazine — 0.65 mcg/mL